Longitudinal Study of the GLUcagon REsponse to Hypoglycemia in Children and Adolescents With New-onset Type 1 DIAbetes

Egyéb feltételek

• WP1 :
• Inclusion criteria:; De novo type 1 diabetic patient, as per ISPAD criteria; Symptoms of hyperglycemia: polyuria-polydipsia-amaigrin +/- Acido ketosis; Fasting blood glucose ≥126 mg/dL AND/OR blood glucose ≥200 mg/dL at 120 minutes of an OGTT AND/OR HbA1c ≥6.5% AND/OR a patient with symptoms of hyperglycemia/hyperglycemic crisis (see 8. a. 2.) with random blood glucose ≥200 mg/dL; Presence in serum of one or more anti-islet autoantibodies (anti-insulin, anti-IA2, anti-GAD65, anti-ZnT8)
• Patients aged between 2 and 30 years
• Minimum weight: 17 kg (for blood samples)
• Male - female patients
• Free, written and oral consent; Exclusion criteria:
• Child under 2 years of age
• Taking treatments interfering with insulin secretion and sensitivity (e.g. sulfonylureas, diazoxide, somatostatin, methylxanthine derivatives, corticosteroids, biguanide, incretins)
• Presence of newly diagnosed (within 1 month) celiac disease (diagnosed on pathological duodenal biopsy) at inclusion
• Autoimmune/autoinflammatory disease (other than type 1 diabetes) or active malignancy present at inclusion
• Obesity defined as a BMI with a z-score >+3 SD
• Hepatic, renal or adrenal insufficiency
• History of bone marrow transplantation
• History of diabetes after hemolytic-uremic syndrome
• Epileptic patient
• Absence of anti-islet autoantibodies
• Dysmorphia with suspicion of underlying genetic syndrome
• Participation in another study in the previous 3 months, with administration of blood derivatives or potentially immunomodulating treatments; WP2 :
• Inclusion Criteria:; De novo type 1 diabetic patient, as per ISPAD criteria; Symptoms of hyperglycemia: polyuria-polydipsia-amaigrin +/- Acido ketosis; Fasting blood glucose ≥126 mg/dL AND/OR blood glucose ≥200 mg/dL at 120 minutes of an OGTT AND/OR HbA1c ≥6.5% AND/OR a patient with symptoms of hyperglycemia/hyperglycemic crisis (see 8. a. 2.) with random blood glucose ≥200 mg/dL; Presence in serum of one or more anti-islet autoantibodies (anti-insulin, anti-IA2, anti-GAD65, anti-ZnT8); Patients aged between 2 years and 18 years (<18 years); Male - female patients; Free, written and oral consent
• Exclusion criteria:; Child under 2 years of age; Taking treatments that interfere with insulin secretion and sensitivity (e.g. sulfonylureas, diazoxide, somatostatin, methylxanthine derivatives, corticosteroids, biguanide, incretins); Presence of newly diagnosed (within 1 month) celiac disease (diagnosed on pathological duodenal biopsy) at inclusion; Autoimmune/autoinflammatory disease (other than type 1 diabetes) or active malignancy present at inclusion; Obesity defined as a BMI with a z-score >+3 SD; Hepatic, renal or adrenal insufficiency; History of bone marrow transplantation; History of diabetes after hemolytic-uremic syndrome; Absence of anti-islet autoantibodies; Dysmorphia with suspected underlying genetic syndrome; Participation in another study within the previous 3 months with administration of blood derivatives or potentially immunomodulatory treatments; WP3 :
• Inclusion Criteria:; Adult older than 18 years; Absence of blood marker of diabetes (Absence of antibodies, HbA1C <6.5%, C-peptide > 0.18 nmol/L, Fasting blood glucose < 100 mg/dL, blood glucose at any time < 200 mg/dL); Be a first-degree relative with a patient being followed for diabetes (meeting ISPAD criteria); Male - Female; Free written and oral consent
• Exclusion criteria:; Taking treatments that interfere with insulin secretion and sensitivity (e.g. sulfonylureas, diazoxide, somatostatin, methylxanthine derivatives, corticosteroids, biguanide, incretins); Presence of newly diagnosed (within 1 month) celiac disease (diagnosed on pathological duodenal biopsy) at inclusion; Autoimmune/autoinflammatory disease (other than type 1 diabetes) or active malignancy present at inclusion; Obesity defined as a BMI with a z-score >+3 SD; Hepatic, renal or adrenal insufficiency; History of bone marrow transplantation; History of diabetes after hemolytic-uremic syndrome; Ischemic cardiomyopathy; Pregnant participant; Epileptic patient; WP4 :
• Inclusion Criteria:; Cohort of patients followed for cystic fibrosis:
• Pediatric patient between 2 and 18 years of age
• Diagnosed with cystic fibrosis with impaired pancreatic endocrine function
• Presents glucose homeostasis disorders (regular hypo/hyper-glycemia)
• Male - female patient
• Free, written and oral consent; Cohort of patients with (sub)total pancreatectomy:
• Pediatric patients between 2 and 18 years of age
• Follow-up for total pancreatectomy or caudal pancreatectomy
• Presents disorders of carbohydrate homeostasis (regular hypo-/hyper-glycemia)
• Male - female patient
• Free, written and oral consent; Exclusion criteria:
• Child under 2 years of age
• Body weight less than 17 kg
• Taking treatments that interfere with insulin secretion and sensitivity (e.g. sulfonylureas, diazoxide, somatostatin, methylxanthine derivatives, corticosteroids, biguanide, incretins)
• Presence of newly diagnosed (within 1 month) celiac disease (diagnosed on pathological duodenal biopsy) at inclusion
• Autoimmune/autoinflammatory disease (other than type 1 diabetes) or active malignancy present at inclusion
• Obesity defined as a BMI with a z-score >+3 SD
• Hepatic, renal or adrenal insufficiency
• History of bone marrow transplantation
• History of diabetes after hemolytic-uremic syndrome
• Dysmorphia with suspected underlying genetic syndrome
• Participation in another study within the last 3 months, with administration of blood derivatives or potentially immunomodulatory treatments; WP5 :
• Inclusion Criteria:; Patient who has undergone insulin testing due to suspected growth hormone deficiency or adrenal insufficiency or hypopituitarism; Patients between the ages of 2 years and 18 years (<18 years); Male - female patient; Free written and oral consent
• Exclusion criteria:; Child under 2 years of age; Body weight less than 17 kg; Taking treatments that interfere with insulin secretion and sensitivity (e.g. sulfonylureas, diazoxide, somatostatin, methylxanthine derivatives, corticosteroids, biguanide, incretins); Presence of newly diagnosed (within 1 month) celiac disease (diagnosed on pathological duodenal biopsy) at inclusion; Autoimmune/autoinflammatory disease (other than type 1 diabetes) or active malignancy present at inclusion; Obesity defined as a BMI with a z-score >+3 SD; History of bone marrow transplantation; History of diabetes after hemolytic-uremic syndrome; Participation in another study within the last 3 months, with administration of blood derivatives or potentially immunomodulatory treatments; WP6 :
• Inclusion Criteria:; Type 1 diabetic patient, as per ISPAD criteria; Symptoms of hyperglycemia: polyuria-polydipsia-amaigrin +/- Acido ketosis; Fasting blood glucose ≥126 mg/dL AND/OR blood glucose ≥200 mg/dL at 120 minutes of an OGTT AND/OR HbA1c ≥6.5% AND/OR a patient with symptoms of hyperglycemia/hyperglycemic crisis (see 8. a. 2.) with random blood glucose ≥200 mg/dL; Presence in serum of one or more anti-islet autoantibodies (anti-insulin, anti-IA2, anti-GAD65, anti-ZnT8); Patients aged between 2 and 18 years (<18 years); Male - female patients; Free, written and oral consent
• Exclusion criteria:; Child under 2 years of age; Taking treatments interfering with insulin secretion and sensitivity (e.g. sulfonylureas, diazoxide, somatostatin, methylxanthine derivatives, corticosteroids, biguanide, incretins); Autoimmune/autoinflammatory disease (other than type 1 diabetes) or active malignancy present at inclusion; Obesity defined as a BMI with a z-score >+3 SD; Hepatic, renal or adrenal insufficiency; History of bone marrow transplantation; History of diabetes after hemolytic-uremic syndrome; Epileptic patient; Dysmorphia with suspicion of underlying genetic syndrome; Participation in another study in the previous 3 months, with administration of blood derivatives or potentially immunomodulating treatments; WP7 :
• Inclusion Criteria:; De novo type 1 diabetic patient, as per ISPAD criteria; Symptoms of hyperglycemia: polyuria-polydipsia-amaigrin +/- Acido ketosis; Fasting blood glucose ≥126 mg/dL AND/OR blood glucose ≥200 mg/dL at 120 minutes of an OGTT AND/OR HbA1c ≥6.5% AND/OR a patient with symptoms of hyperglycemia/hyperglycemic crisis (see 8. a. 2.) with random blood glucose ≥200 mg/dL; Presence in serum of one or more anti-islet autoantibodies (anti-insulin, anti-IA2, anti-GAD65, anti-ZnT8); Patients aged between 2 and 18 years; Minimum weight: 17 kg (for blood samples); Male - female patients; Free, written and oral consent
• Exclusion criteria:; Child under 2 years of age; Taking treatments interfering with insulin secretion and sensitivity (e.g. sulfonylureas, diazoxide, somatostatin, methylxanthine derivatives, corticosteroids, biguanide, incretins); Presence of newly diagnosed (within 1 month) celiac disease (diagnosed on pathological duodenal biopsy) at inclusion; Autoimmune/autoinflammatory disease (other than type 1 diabetes) or active malignancy present at inclusion; Obesity defined as a BMI with a z-score >+3 SD; Hepatic, renal or adrenal insufficiency; History of bone marrow transplantation; History of diabetes after hemolytic-uremic syndrome; Epileptic patient; Absence of anti-islet autoantibodies; Dysmorphia with suspicion of underlying genetic syndrome; Participation in another study in the previous 3 months, with administration of blood derivatives or potentially immunomodulating treatments